Fabrazyme

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist.

FABRAZYME contains the active ingredient agalsidase beta-rch. FABRAZYME is used as enzyme replacement therapy in Fabry Disease. For more information, see Section 1. Why am I being given FABRAZYME? in the full CMI.

You or your child should not be given FABRAZYME if you or your child have ever had an allergic reaction to agalsidase beta or any of the ingredients listed at the end of the CMI.

Talk to your doctor if you or your child have any other medical conditions, take any other medicines, or if you are pregnant or plan to become pregnant or are breastfeeding.

For more information, see Section 2. What should I know before I am given FABRAZYME? in the full CMI.

Some medicines may interfere with FABRAZYME and affect how it works. Check with your doctor if you are not sure about what medicines, vitamins or supplements you or your child are taking and if these affect FABRAZYME.

For more information, see Section 3. What if I am taking other medicines? in the full CMI.

More information can be found in Section 4. How is FABRAZYME given? in the full CMI.

For more information, see Section 5. What should I know while being given FABRAZYME? in the full CMI.

Common and less serious side effects include headaches, dizziness and lightheadedness, sleepiness, local reaction around the injection site such as redness, itchiness, tenderness, pain or discomfort, warmth, burning or stinging, swelling or the formation of hard lumps or scars, runny nose, flushing or redness of the skin, pale skin, soreness, aching muscles, muscle tenderness, weakness (not caused by exercise), shaking or pins and needles, nausea, vomiting, and stomach-ache.
Serious side effects include signs of allergic reaction (shortness of breath, wheezing or difficulty breathing, swelling of the face, lips, tongue or other parts of the body, skin rash, itching or hives), difficulty swallowing, changes in your heartbeat (increase or decrease), and chest pain.
For more information, including what to do if you have any side effects, see Section 6. Are there any side effects? in the full CMI.

Active ingredient(s): agalsidase beta-rch (ag-al-SI-daze bee-ta R.C.H)

This leaflet provides important information about using FABRAZYME. You should also speak to your doctor or pharmacist if you would like further information or if you have any concerns or questions about using FABRAZYME.

Where to find information in this leaflet:

FABRAZYME contains the active ingredient agalsidase beta-rch. FABRAZYME is a recombinant human α-galactosidase. Patients with Fabry Disease do not produce enough of their own α-galactosidase enzyme. Reduced levels of α-galactosidase enzyme results in the accumulation of substances called glycosphingolipids in a number of cell types and tissues.

FABRAZYME is used as enzyme replacement therapy in Fabry Disease. It is intended to restore a level of enzyme activity sufficient to remove the accumulated substances and to prevent further accumulation.

During treatment, you or your child may be at risk of developing certain side effects. It is important you understand these risks and how to monitor for them. See additional information under Section 6. Are there any side effects?

Check with your doctor if you are pregnant or intend to become pregnant.

There is no information available regarding the use of FABRAZYME in pregnant women.

Your treating doctor will discuss the possible risks and benefits of receiving FABRAZYME during pregnancy.

Talk to your doctor if you are breastfeeding or intend to breastfeed.

FABRAZYME is not recommended for use when breast-feeding as it is not known whether FABRAZYME passes into breast milk. If there is a need to consider using FABRAZYME while you are breast-feeding, your treating doctor will discuss with you the benefits and risks of using it.

Tell your doctor if your child is under 8 years of age and has been prescribed FABRAZYME.

Safety in children below the age of 8 years has not been studied. If your child has been prescribed FABRAZYME, you may wish to discuss this with your child's treating doctor.

Tell your doctor or nurse if you or your child are taking any other medicines, including any medicines, vitamins or supplements that you buy without a prescription from your pharmacy, supermarket or health food shop.

Check with your doctor if you are not sure about what medicines, vitamins or supplements you or your child are taking and if these affect FABRAZYME.

Your treating doctor is trained to work out the correct dose and to phone the Poisons Information Centre (by calling 13 11 26), in case of an overdose. There have been no reported overdoses of FABRAZYME.

If you think that you or your child have been given too much FABRAZYME, you may need urgent medical attention.

Keep appointments with your treating doctor or clinic.

It is important for you or your child to receive FABRAZYME infusions at the appropriate times to make sure the medicine has the best chance of providing treatment for the condition.

Have any tests when your treating doctor says to.

Your treating doctor may wish to test you or your child's body's response to FABRAZYME to make sure that it is working.

Remind any doctor, dentist or pharmacist you or your child visit that you or your child are being treated with FABRAZYME.

Be careful before you drive or use any machines or tools until you know how FABRAZYME affects you.

FABRAZYME may cause dizziness, lightheadedness, tiredness and sleepiness in some people.

Make sure that you know how you react to FABRAZYME before you drive a car or operate machinery or do anything else that may be dangerous if you are dizzy, lightheaded, tired or drowsy.

Children should be careful when undertaking activities requiring attention such as riding bicycles or climbing.

The effect of FABRAZYME on your ability to drive a car or operate machinery has not been studied.

FABRAZYME will be stored in the hospital or clinic pharmacy.

FABRAZYME will be used immediately after it has been prepared for infusion.

All medicines can have side effects. If you or your child do experience any side effects, most of them are minor and temporary. However, some side effects may need medical attention.

See the information below and, if you need to, ask your doctor, nurse or pharmacist if you have any further questions about side effects.

Tell your doctor or nurse if you notice anything else that may be making you or your child feel unwell while you or your child are being given FABRAZYME, or soon after having finished being given FABRAZYME.

Other side effects not listed here may occur in some people.

After you or your child have received medical advice for any side effects you or your child experience, you can report side effects to the Therapeutic Goods Administration online at www.tga.gov.au/reporting-problems . By reporting side effects, you can help provide more information on the safety of this medicine.

Always make sure you speak to your doctor or pharmacist before you decide to stop taking any of your medicines.

This medicine is only available with a doctor's prescription.

Do not take this medicine if you are allergic to any of these ingredients.

FABRAZYME is a white to off-white powder before it is prepared for infusion and a clear, colourless solution after it has been prepared for infusion.

FABRAZYME 5 mg is supplied in clear 5 mL glass vials (Aust R 94000).

FABRAZYME 35 mg is supplied in clear 20 mL glass vials (Aust R 82755).

Each pack contains 1 vial.

Distributed by:

sanofi-aventis australia pty ltd

12-24 Talavera Road

Macquarie Park NSW 2113

Freecall: 1800 818 806

Email: [email protected] 

This leaflet was prepared in November 2024.

fabr-ccdsv4-cmiv6-15nov24

FABRAZYME® is a registered trademark of Genzyme Corporation, USA.